Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Original abstract verifies 467450 children, about 2.99 million person-years, autism RR 0.85(CI 0.60–1.20) and dose slope per 25 micrograms0.98(CI 0.90–1.06). Provider's numerical outline agrees, but absence of an observed effect is finite-precision evidence, not a proof that every rare event is impossible. Our access was original abstract/status, not complete full text. Original PMID14519711. Access: abstract_metadata.
Original abstract verifies657461 children, adjustedHR 0.93(CI 0.85–1.02), no consistent increased risk in specified familial-risk/timing groups, and explicitly no individual chart review. Provider numbers agree; 'no subgroup vulnerability' must remain limited to tested definitions and their precision. Original access was abstract/status. Original PMID30831578. Access: abstract_metadata.
Original abstract verifies2,560,035 children, MMR aHR 0.97(99% CI 0.91–1.03) and pneumococcal negative-controlaHR 1.01(0.99–1.04). Provider's claim that this excludes residual confounding is rejected: it tests specified shared bias pathways and cannot exclude all unmeasured/measurement confounding. Original access was abstract/status; no body audit was claimed. Original PMID42520244. Access: abstract_metadata.
Original abstract verifies Colorado exemption-associated measlesRR22.2 andpertussisRR5.9, plus community incidence/contact findings. Provider attached broad infection-protection claims to secondary reviews and unrelated Geier references rather than this requested original. The review uses the actual original and distinguishes nonrandom refusal/contact clustering from randomized efficacy. Original access was abstract/status. Original PMID11135778. Access: abstract_metadata.
Original abstract verifies randomized pertussis components versus DT-only control, product-specific clinical efficacy and higher whole-cell reactogenicity. This supplies actual intervention causality for the infection-risk branch and prevents a universal zero-adverse-effect framing. Original access was abstract/status, with linked erratum details unexamined. Original PMID8538705. Access: abstract_metadata.
Original abstract verifies randomized varicella-antigen schedules versus MMR-only control, ten-year confirmed-varicella protection and stronger two-dose efficacy. The Russian sample is a subset of one internationalNCT00226499 trial, not an extra independent trial. Original access was abstract/status. Original PMID34435933. Access: abstract_metadata.
Original Results5–8 verify faster blood clearance after thimerosal than methylmercury but slower brain than blood clearance and retained inorganic mercury. Provider's shorter-half-life summary is incomplete if taken to mean no brain retention. These kinetic findings do not establish clinical autism; our access includes selected original body passages. Original PMID16079072. Access: full_text_partial.
Original Methods0/1/7 show late-preterm infants at 32–37 weeks, vaccine exposure, one pre/post sample per infant and population-based half-life modeling. The abstract's6.3 dayestimate is not repeated individual serial kinetics, evidence for very-preterm infants, or an autism-incidence endpoint. Our access includes selected original Methods. Original PMID19560158. Access: full_text_partial.
Original Methods1/3–5 and Results14/20/26/28/30 show that every participant received initial active DMSA, with one-versus-seven-round randomization and no significant reported between-group symptom advantage. Both within-group changes and post-dose metal regressions cannot prove placebo-controlled efficacy or vaccine-caused autism. Part A(PMID 19852789) is the same trial, not an independent primary study; our access includes selected original body. Original PMID19852790. Access: full_text_partial.
Original Methods3/4/6 verify chart review, medical-officer Brighton adjudication and a per-dose denominator. The abstract reports33 cases/25,173,965 doses, or1.31 per million doses, across children/adults. Provider's general rare-adverse-event statement is strengthened with actual original evidence, while autism remains a separate outcome. Our access includes selected original Methods. Original PMID26452420. Access: full_text_partial.
Original abstract verifies first-doseMMRVversusseparate MMR plus varicella seizureRR1.98 andaboutoneexcessfebrileseizureper2300 doses in 12–23 month-olds. The older4–6 yearstudy(PMID 22473362) differs. This is an acknowledged safety boundary, not evidence for autism or a blanket avoidance policy. Original access was abstract/status. Original PMID20587679. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.